Lamotrigine for cognitive deficits associated with neurofibromatosis type 1: A phase <scp>II</scp> randomized placebo‐controlled trial

Publication Details

Journal
Developmental Medicine & Child Neurology
Published
2024-10-26
DOI
https://doi.org/10.1111/dmcn.16157
Primary Topic
Neurofibromatosis and Schwannoma Cases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lamotrigine for cognitive deficits associated with neurofibromatosis type 1: A phase II randomized placebo‐controlled trial

Developmental Medicine & Child Neurology
Neurofibromatosis and Schwannoma Cases
article

Lamotrigine for cognitive deficits associated with neurofibromatosis type 1: A phase II randomized placebo‐controlled trial

article en

Abstract

No abstract available for this paper.
Developmental Medicine & Child NeurologyVol. 66(12)
Good health and well-being
Openalex Percentile: Top 70%
Neurofibromatosis and Schwannoma Cases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Lamotrigine for cognitive deficits associated with neurofibromatosis type 1: A phase <scp>II</scp> randomized placebo‐controlled trial · Developmental Medicine & Child Neurology (2024) | TGRS Research Map | TGRS